Moxonidine-SZ, 0.2 mg 90 pcs

Pharmacotherapeutic drug group:

Hypotensive drug of central action.

ATC code: [C02AC05]

Pharmacodynamics

Moxonidine is a hypotensive drug with a central mechanism of action. In brain stem structures (rostral layer of lateral ventricles) moxonidine selectively stimulates imidazoline-sensitive receptors involved in tonic and reflex regulation of the sympathetic nervous system. Stimulation of imidazoline receptors reduces peripheral sympathetic activity and blood pressure (BP).

Moxonidine differs from other sympatholytic hypotensive agents in its lower affinity for α2-adrenoreceptors, which explains the lower probability of developing sedation and dry mouth. Administration of moxonidine results in reduction of systemic vascular resistance and BP. Moxonidine improves insulin sensitivity index (compared to placebo) by 21 % in patients with obesity, insulin resistance and moderate arterial hypertension. Pharmacokinetics

Intake:

After oral administration, moxonidine is rapidly and almost completely absorbed in the upper gastrointestinal tract. Absolute bioavailability is approximately 88%. Time of reaching maximum concentration is; about 1 hour. Food intake has no effect on the pharmacokinetics of the drug.

Distribution

The binding to plasma proteins is 7.2%.

Metabolism

The main metabolite is; dehydrated moxonidine. The pharmacodynamic activity of dehydrated moxonidine is; about 10% compared to moxonidine. Excretion The elimination half-life (T1/2) of moxonidine and the metabolite is 2.5 and 5 hours, respectively. Within 24 hours, over 90% of moxonidine is excreted by the kidneys (approximately 78% unchanged and 13% as dehydro-romoxonidine, other metabolites in the urine do not exceed 8% of the dose taken). Less than 1% of the dose is excreted through the intestine.

Pharmacokinetics in patients with arterial hypertension: Compared with healthy volunteers, patients with arterial hypertension show no changes in the pharmacokinetics of moxonidine.

Pharmacokinetics in the elderly

Clinically insignificant changes in the pharmacokinetic parameters of moxonidine have been observed in elderly patients, probably due to a decrease in its metabolic rate and/or slightly higher bioavailability.

Pharmacokinetics in children

Moxonidine is not recommended for use in patients younger than 18 years of age; therefore, no pharmacokinetic studies have been performed in this group. Pharmacokinetics in renal failure

The excretion of moxonidine is highly correlated with creatinine clearance (CK). In patients with moderate renal insufficiency (CK between 30-60 mL/min), equilibrium plasma concentrations and final T1/2 are approximately 2 and l.5 times higher than in patients with normal renal function (CK greater than 90 mL/min).

In patients with severe renal impairment (CKR less than 30 mL/min), equilibrium plasma concentrations and final T1/2 are 3 times higher than in patients with normal renal function. Administration of multiple doses of moxonidine results in predictable cumulation in patients with moderate to severe renal impairment.

In patients with terminal renal failure (KC less than 10 ml/min) on hemodialysis, equilibrium plasma concentrations and final T1/2 are 6 and 4 times higher, respectively, than in patients with normal renal function. In all groups, the maximum plasma concentration of moxonidine is 1.5 to 2 times higher. In patients with impaired renal function the dosage should be adjusted individually. Moxonidine is slightly excreted during hemodialysis.

Indications

Hypertension (high blood pressure)Arterial hypertension.

Active ingredient

Moxonidine

Composition

Active substance:

moxonidine 0.2 mg

auxiliary substances (core):

croscarmellose sodium (primellose) – 3.0 mg;

lactose monohydrate (lactopress) (milk sugar) -; 95.3 mg;

p> colloidal silicon dioxide (aerosil) -; 0.5 mg;

sodium stearyl fumarate -; 1.0 mg;

accompaniments (coating):

Opadray II (polyvinyl alcohol, partially hydrolyzed -; 1.32 mg; E 171 titanium dioxide -; 0.6027 mg; talc -; 0.6 mg; macrogol (polyethylene glycol 3350) -; 0.3705 mg; soy lecithin E 322 -; 0.105 mg; iron oxide (II) yellow dye -; 0.0003 mg; iron oxide (II) red dye -; 0.0015 mg).

How to take, the dosage

Ingestion, regardless of meals. In most cases, the initial dose of the drug

Moxonidine is 0.2 mg per day. The maximum single dose is 0.4 mg. The maximum daily dose to be divided into 2 doses is 0.6 mg.

An individual adjustment of the daily dose is necessary depending on the patient’s tolerance to the ongoing therapy. No dose adjustment is required for patients with hepatic insufficiency.

The starting dose for patients with moderate to severe renal insufficiency is 0.2 mg/day. If necessary and if well tolerated, the daily dose may be increased to a maximum of 0.4 mg.

Interaction

The co-administration of moxonidine with other antihypertensive agents leads to additive effects.

Tricyclic antidepressants may decrease the effectiveness of central antihypertensive agents, and therefore their simultaneous use with moxonidine is not recommended.

Moxonidine may increase the effect of tricyclic antidepressants, tranquilizers, ethanol, sedatives and hypnotics. Moxonidine may moderately improve impaired cognitive function in patients receiving lorazepam.

Moxonidine may increase the sedative effect of benzodiazepine derivatives when used concomitantly.

Moxonidine is excreted by tubular secretion, therefore interaction with other drugs excreted by tubular secretion cannot be excluded.

Beta-adrenoblockers increase bradycardia, the severity of negative and dromotropic effects.

Directions for use

The drug is taken orally, regardless of meals.

In most cases, the starting dose of Moxonidine-SZ is 0.2 mg/day. The maximum single dose is 0.4 mg. The maximum daily dose to be divided into 2 doses is 0.6 mg. Individual adjustment of the daily dose is necessary depending on the patient’s tolerance to the therapy.

Dose adjustment is not required for patients with hepatic impairment.

The starting dose for patients with moderate to severe renal failure is 0.2 mg/day. If necessary and if well tolerated, the daily dose can be increased to a maximum of 0.4 mg.

Special Instructions

If it is necessary to withdraw beta-adrenoblockers and Moxonidine-SZ taken simultaneously, the beta-adrenoblockers should be withdrawn first and only after several days Moxonidine-SZ. There is currently no evidence that discontinuation of Moxonidine-SZ leads to an increase in BP. However, it is not recommended that Moxonidine-SZ be stopped abruptly; instead, the dose should be gradually reduced over a 2 week period.

Alcohol should be avoided during treatment.

During treatment, regular monitoring of HR and ECG is necessary.

The effect of Moxonidine-SZ on driving and operating ability has not been studied. However, taking into account the possibility of dizziness and somnolence, patients should be careful when driving vehicles and engaging in other activities requiring increased concentration.

Contraindications

• Severe renal failure (CK less than 30 ml/min);
• Major heart rhythm disorders;
• CSU;
• Severe bradycardia (resting heart rate less than 50 beats/min.
• AV-blockade of degree II and III;
• acute and chronic heart failure (NYHA functional class III-IV);

.

• concomitant use with tricyclic antidepressants;
• hemodialysis;
• lactation period;
• age above 75 years;
• age
• under 18 years of age (due to lack of safety and efficacy data)
• hereditary lactose intolerance, lactase deficiency or glucose-galactose malabsorption;
• high sensitivity to the active substance and other components of the drug.

Cautions

Particular caution should be exercised when using moxonidine in patients with AV blockade of degree I (risk of bradycardia); severe coronary artery disease, severe CHD or unstable angina (insufficient experience of use), chronic heart failure, severe hepatic insufficiency, renal impairment (CK more than 30 ml/min).

Side effects

The frequency of side effects listed below was determined accordingly as follows: very frequently (>1/10); frequently (>1/100, <1/10); infrequently (>1/1000, <1/100); including individual reports.

CNS disorders: frequent – headache*, dizziness (vertigo), somnolence; infrequent – fainting*.

Psychiatric disorders: often – insomnia; infrequently – nervousness.

Hearing and labyrinth disorders: infrequent – tinnitus.

Cardiovascular system: infrequent – significant decrease in BP, orthostatic hypotension*, bradycardia.

Digestive system disorders: very frequently – dry mouth; frequently – diarrhea, nausea, vomiting, dyspepsia.

Skin and subcutaneous tissue: often – skin rash, itching.

Muscular system: often – back pain; infrequently – pain in the neck.

Allergic reactions: infrequent – angioedema.

General disorders and disorders at the site of administration: often – asthenia; infrequently – peripheral edema.

* – frequency is comparable to placebo.

Overdose

There have been reports of several non-fatal overdoses when doses up to 19.6 mg were used at one time.

Symptoms: headache, sedation, excessive BP decrease, dizziness, asthenia, bradycardia, dry mouth, vomiting, increased fatigue, epigastric pain, respiratory depression and impaired consciousness. In addition, transient BP elevation, tachycardia, and hyperglycemia are also possible, as has been shown in several high-dose animal studies.

Treatment: there is no specific antidote. In cases of excessive BP decrease it may be necessary to restore the blood pressure by administration of fluids and dopamine (by injection). Bradycardia may be controlled with atropine (injection).

In severe cases of overdose, it is recommended to carefully control impaired consciousness and avoid respiratory depression. α-adrenoceptor antagonists may reduce or eliminate the paradoxical hypertensive effects of moxonidine overdose. Moxonidine is slightly excreted by hemodialysis.

Pregnancy use

Pregnancy

There are no clinical data on the use of Moxonidine in pregnant women.

In animal studies, embryotoxic effects of the drug have been established. Moxonidine should be administered to pregnant women only after careful assessment of the risk/benefit ratio, when the benefit to the mother exceeds the potential risk to the fetus.

Lactation period

Moxonidine penetrates into breast milk and therefore should not be administered while breastfeeding. If it is necessary to use Moxonidine during lactation, breastfeeding should be stopped.

Similarities

Moxonidine, Moxonitex, Tensotran, Physiotensis, Moxarel